



Salugen Biosciences, Inc.

877-258-4360
www.Salugen.com

4660 La Jolla Village Drive
Suite 500
San Diego, CA 92122

SALUGEN BIOSCIENCES WELCOMES NATIONAL ACADEMIES’ REPORT ON U.S. PAIN MANAGEMENT

Personalized pain medicine laboratory Salugen Biosciences agrees that pain management and the appropriate use of therapies needs to be a national concern

SAN DIEGO, CA (June 6, 2011) – Salugen Biosciences, Inc., the personalized pain medicine laboratory services company, praised the report from the National Academies’ Institute of Medicine released on June 29th entitled “Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.” The 2010 Patient Protection and Affordable Care Act required the Department of Health and Human Services (HHS) to enlist the IOM in examining pain as a public health problem.

The report estimates that 116 million American adults suffer from chronic pain, more than those affected by heart disease, cancer and diabetes combined.

The IOM also noted that pain costs the U.S. up to \$635 billion each year in medical treatment and lost productivity. The report focuses on the use of “better data” by healthcare providers to “increasingly aim at tailoring pain care to each person’s experience.”

“This independent report is vital to raising awareness about the current failings of pain management and the importance of tailoring treatment to the individual patient,” states Brian Meshkin, Executive Chairman of Salugen Biosciences. “It also underscores the clinical and economic benefits we’ve observed over the past two years as pain medicine prescribers have been using our genetic testing to identify patients at risk for opioid abuse to optimize therapies.”



Salugen Biosciences, Inc.

877-258-4360
www.Salugen.com

4660 La Jolla Village Drive
Suite 500
San Diego, CA 92122

According to the National Institute of Health, about 60% of addictions are due to genetic factors.¹ However, physicians rarely evaluate genetic factors when they prescribe narcotics. Prescription pain medication abuse is a rising epidemic.

Three times as many persons are addicted to or die from prescription pain medications than all illegal drugs combined.²

Salugen Biosciences' proprietary HAVEOS Genetics Abuse Profile testing is the first of its kind to help physicians identify patients genetically at-risk for opioid abuse, dependence, or tolerance. The HAVEOS Genetics Abuse Profile analyzes a panel of 12 single nucleotide polymorphisms to construct a genetic risk profile based on chemical imbalances in the mesolimbic dopamine system of the brain. After two years of limited commercial utilization in southern California and south Florida, the Company is now expanding its testing services nationwide.

About Salugen Biosciences

Salugen® Biosciences, Inc. is a biotechnology company that develops and markets proprietary laboratory tests to personalize pain medicine therapies.

Salugen's proprietary technology helps patients avoid or eliminate prescription pain medication abuse, helps insurers control costs, and provides tools clinicians need to improve treatment outcomes. Salugen Biosciences is the personalized pain medicine laboratory services company. For more information, please visit

www.salugen.com or call toll free 877-258-4360.

¹ Nora Volkow. Drugs, Brains, and Behavior - The Science of Addiction. National Institutes of Drug Abuse, National Institutes of Health. 2010.

² Liz Szabo, "Prescriptions Now Biggest Cause of Fatal Drug Overdoses," *USA Today*, 9/30/2009